New BioSilicon patents granted
01 June, 2004 by Graeme O'NeillThe patents keep rolling in for Perth biotech-nanotech company Psivida (ASX:PSD), which has announced that the European Patent Office (EPO) has granted its UK operating subsidiary pSiMedica another patent on biodegradable silicon implants for drug delivery.
Vision Biosystems' tissue processor 'hits the ground running'
01 June, 2004 by Melissa TrudingerMelbourne-based equipment manufacturer Vision Biosystems, part of the Vision Systems group (ASX:VSL), has launched its Peloris tissue processor in Australia, and plans to launch the instrument in international markets as well.
Prana shareholders approve US capital raising
01 June, 2004 by Renate KrellePrana (ASX: PBT; NASDAQ: PRAN) shareholders today gave the stamp of approval to the company's AUD$28 million capital raising, voting in favour of the sale to US institutional investors of 3 million ADRs at US$5 per ADR.
Roche's anaemia therapy trial gets underway worldwide
01 June, 2004 by Graeme O'NeillSwiss pharmaceutical giant Roche has begun a massive, 484-centre Phase III trial of its new drug for anaemia associated with chronic kidney disease.
Eiffel's Nasdaq view improves as ADR completed
01 June, 2004 by Melissa TrudingerEiffel Technologies (ASX:EIF) has established a Level 1 American Depository Receipt (ADR) program in a first step towards a possible international listing for the company.
BresaGen merger still looks likely
01 June, 2004 by Melissa Trudinger and Renate KrelleThe merger of BresaGen's US-based cell therapy division with San Diego stem cell company Cythera looks like it will go ahead, after the two companies executed the merger agreement last week.
Biosignal animal studies show efficacy
31 May, 2004 by Melissa TrudingerBiosignal (ASX:BOS) has confirmed the efficacy of its furanone molecules in preventing bacterial colonisation of contact lenses in animal studies, paving the way for more extensive human studies.
Ambri to evaluate SensiDX in hospitals
31 May, 2004 by Melissa TrudingerAmbri (ASX:ABI) has installed its SensiDX System at the Royal North Shore Hospital in Sydney for evaluation and expects to install a second system at Sydney's St Vincent's Hospital shortly.
New faces at the Bionomics
27 May, 2004 by Graeme O'NeillAdelaide drug-discovery company Bionomics (ASX:BNO, US OTC:BMICY) has appointed Dr Tim Harris, CEO and co-founder of US biotech Structural GenomiX, to its advisory board.
Ventracor pilot trial to continue
27 May, 2004 by Renate KrelleSydney-based Ventracor (ASX:VCR) today announced its pilot trial, testing the safety of its VentrAssist artifical heart device, will continue.
Phosphagenics seeks listing on UK's AIM
26 May, 2004 by Renate KrelleMelbourne-based Phosphagenics (ASX:POH) -– formerly Vital Capital -– has flagged its intention to seek a dual listing on the London Stock Exchange's Alternative Investment Market (AIM).
CSL outsources anti-venom production to PlasVacc
25 May, 2004 by Melissa TrudingerQueensland based veterinary plasma company PlasVacc has signed and agreement to supply CSL with horse plasma for anti-venom applications.
Fed decision backs GSK lawsuit, says Biota
25 May, 2004 by Melissa TrudingerA federal government decision earlier this month to stockpile Roche's Tamiflu, rather than the anti-flu drug Relenza, designed by Melbourne-based Biota (ASX:BTA), is being used by the Australian firm to support its legal claims that GlaxoSmithKline failed to support and promote Relenza.
Cryosite and Peter Mac team up to store stem cells
24 May, 2004 by Melissa TrudingerSydney-based cryogenic storage company Cryosite (ASX: CTE) has entered into an agreement with Melbourne's Peter MacCallum Cancer Centre to provide long term storage of patients' blood stem cells.
Parental approval for BioPharmica spin off, prospectus launched
24 May, 2004 by Melissa TrudingerThe spin-off and listing of BioPharmica was approved at a general meeting of Grandbridge (ASX: GBA) shareholders today by more than 99 per cent of shareholders.
